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Abstract
Background: Hepatic encephalopathy has a negative impact on health-related quality of life (QoL)
in liver cirrhosis. There are scarce and conflicting data on whether type or etiology of liver cirrhosis
could be related to hepatic encephalopathy in patients with cirrhosis. We aimed to determine the
impact of cirrhosis etiology on hepatic encephalopathy and whether hepatic encephalopathy affects
health-related QoL among patients with cirrhosis of different etiologies.
Methods: A total of 156 cirrhotic patients were prospectively evaluated for the presence of
hepatic encephalopathy according to the West-Haven criteria as well as by means of two
psychometric tests. Patients with cryptogenic cirrhosis or cirrhosis due to mixed hepatocellular/
cholestatic etiologies were excluded. Fasting plasma glucose levels were also measured. QoL was
evaluated by means of a validated questionnaire (SF-36).
Results: Diabetes mellitus was more common in patients with hepatocellular cirrhosis compared
to those with cholestatic cirrhosis but the two groups did not differ in cirrhosis severity or the
prevalence of hepatic encephalopathy (p > 0.05). The groups of patients with cirrhosis due to
alcohol, hepatitis C, or cholestatic liver disease did not differ in severity of liver cirrhosis or the
prevalence of hepatic encephalopathy (p > 0.05). Patients with cirrhosis of different etiologies did
not differ in any SF-36 domain (p > 0.05). In multivariate analysis, performance at
neuropsychological testing was independently related only to age, diabetes mellitus, and the Child-
Pugh score whereas the SF-36 physical component summary only to the Child-Pugh score and
hepatic encephalopathy.
Conclusion: Cirrhosis etiology does not seem to be related to hepatic encephalopathy or health-
related QoL. Cognitive impairment is associated mainly with age, liver disease severity and diabetes
mellitus.
Background
Patients with liver cirrhosis are prone to develop cognitive
dysfunction termed hepatic encephalopathy (HE). The
clinical manifestations of HE range from subtle intellec-
tual and personality changes, that can be detected only by
means of neuropsychological and neurophysiological
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tests (i.e. minimal HE), to coma [1]. The pathogenesis of
HE is incompletely understood but ammonia is consid-
ered to play a central role [1,2].
Published data on cognitive impairment in cirrhosis due
to cholestatic liver disease compared to cirrhosis due to
hepatocellular disease are few and conflicting [3,4].
Recently diabetes mellitus was found to be associated
with HE in hepatitis C cirrhosis [5] and with performance
at neuropsychological cognitive testing in an unselected
cirrhotic population [6]. The prevalence of diabetes melli-
tus is known to vary according to the etiology of cirrhosis,
being higher in patients with cirrhosis due to hepatitis C
or alcoholic liver disease (hepatocellular disease) com-
pared to patients with cirrhosis due to cholestatic liver dis-
ease [7]. However, it is unknown whether any potential
difference in the prevalence of HE between cholestatic and
hepatocellular cirrhosis can be explained by the different
prevalence of diabetes mellitus in these groups of patients.
Previous studies have explored cognitive function in alco-
holic patients as well as in patients with chronic hepatitis
C and primary biliary cirrhosis (PBC), and all have been
reported to have cognitive impairment in the absence of
cirrhosis [8-12]. However few investigations have assessed
the importance of etiology of liver disease for cognitive
function in cirrhosis [13-15] and data on the potential
effect of liver disease etiology on minimal or overt HE
diagnosed according to currently accepted criteria [16] are
scarce.
Health-related quality of life (QoL) is impaired in patients
with cirrhosis [17-20]. Liver disease severity [17,18,20]
and hepatic encephalopathy [17,21] are known to have a
negative impact on QoL in this group of patients.
Although most studies have shown that the etiology of cir-
rhosis does not have any major effect on QoL [17,19,20],
published data are not unanimous as patients with chole-
static cirrhosis have been reported to have less impair-
ment in QoL than patients with hepatocellular cirrhosis
[18]. Furthermore, it is unknown whether potential differ-
ences in the prevalence of hepatic encephalopathy in
patients with cirrhosis of different etiologies are reflected
in health-related QoL.
The primary aim of the current study was to investigate the
relation of the type (hepatocellular vs. cholestatic) and
etiology of liver cirrhosis with the presence of hepatic
encephalopathy. We also aimed to evaluate the relation of
etiology of liver disease with health-related QoL (particu-
larly in view of potential differences in the prevalence of
hepatic encephalopathy among groups of cirrhotic
patients with different etiologies).
Methods
Patients
Consecutive adult patients with liver cirrhosis admitted to
the gastroenterology ward or attending the outpatient
clinic of the gastroenterology department at a transplant
center in Sweden were prospectively enrolled. Inclusion
criterion was liver cirrhosis of any cause. The diagnosis of
liver cirrhosis was established histologically or based on
the presence of at least 2 of the following: characteristic
imaging features, esophageal or gastric varices, ascites,
increased international normalized ratio (INR) that could
not be attributed to any other cause. Patients unable to
understand Swedish as well as those unable to give written
informed consent or to fill in questionnaires (e.g. due to
severe comorbidities such as dementia and psychosis, or
debilitating hepatic encephalopathy) were excluded. Also
excluded were patients with cryptogenic cirrhosis, mixed
hepatocellular and cholestatic chronic liver disease (e.g.
overlap syndrome), or with cirrhosis after liver transplan-
tation. Patients with cryptogenic cirrhosis were excluded
as the underlying etiology is unclear. Although a history of
alcohol abuse is lacking in these patients it is difficult to
exclude with certainty an alcoholic etiology in some. It
has been recognized, in recent years, that a significant pro-
portion of patients with cryptogenic cirrhosis might be
due to a long-standing non-alcoholic steatohepatitis
(NASH). Patients with NASH cirrhosis were included in
the current study only if NASH had been appropriately
diagnosed prior to cirrhosis development. Patients with
unknown cirrhosis etiology despite extensive investiga-
tions and in the absence of a history of diagnosed NASH
prior to cirrhosis development were excluded to allow
proper allocation of enrolled patients to type and etiology
groups. Out of 176 consecutive patients who fulfilled the
inclusion criteria and were approached, 156 patients
(87%) agreed to participate in the study and completed
the questionnaires. Patients hospitalized because of acute
diseases or complications related to liver disease were
evaluated when stable clinical conditions were reached.
No patient was on dialysis and none had hepatorenal syn-
drome. Patient data were collected from medical records,
including etiology of liver disease, previous variceal bleed-
ing, existing esophageal or fundic varices, and hepatocel-
lular carcinoma. No patient was receiving interferon
therapy at inclusion in the study. Serum albumin and
bilirubin as well as fasting plasma glucose and the INR
were measured by standard in-house methods. Patients
were considered having diabetes if they were receiving
antidiabetic treatment (oral hypoglycemic agents or insu-
lin) or had elevated fasting plasma glucose levels (> 7
mmol/l). The severity of the liver disease was assessed
according to the Child-Pugh classification and the Model
for end-stage liver disease (MELD) score [22]. The pres-
ence of ascites was evaluated by means of abdominal
ultrasonography upon inclusion in the study. Patient filesBMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
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were carefully scrutinized in order to ascertain the
grounds on which the diagnosis of the etiology of cirrho-
sis was established. Patients with cirrhosis due to alco-
holic liver disease, viral or autoimmune hepatitis, or
NASH were designated as the group with hepatocellular
cirrhosis whereas patients with PBC or primary sclerosing
cholangitis (PSC) were designated as the cholestatic
group. The study protocol was approved by the ethics
committee of the University of Gothenburg and all
patients gave written informed consent before participa-
tion.
Evaluation of hepatic encephalopathy
HE was evaluated according to the guidelines proposed by
the 11th World Congress of Gastroenterology in 1998
[16]. It was graded clinically on a scale from 0 to 4 accord-
ing to the West-Haven criteria and cognitive function was
also assessed (on the same day) by means of two psycho-
metric tests the number connection test A and B (NCT-A/
B) [16]. Instructions for administration of NCT-A and B
were strictly followed [23]. Every effort was undertaken to
rule out concomitant neurologic disease (such as cere-
brovascular events, subdural hematoma, Wernicke's dis-
ease, drug intoxication) as indicated clinically. The results
of NCT-A and B of each patient were compared to age-cor-
rected normal values obtained from the general popula-
tion [23]. On the same day as clinical evaluation for HE
and administration of NCT-A and B were performed, fast-
ing venous blood samples were drawn from every patient
for plasma ammonium ion measurement which was per-
formed directly according to a standard in-house method.
Minimal hepatic encephalopathy was defined as absence
of overt hepatic encephalopathy assessed by the West-
haven criteria and NCT-A > 3 standard deviations (SD)
and/or NCT-B > 3SD of the general population [16,23].
Assessment of health-related quality of life
The generic health-related QoL instrument Short Form-36
(SF-36) was developed as a comprehensive measure of
general health status for use in the Medical Outcomes
Study, and has been thoroughly tested for validity and
reliability [24-27]. This questionnaire assesses the extent
to which an individual's health limits physical, emo-
tional, and social functioning. It consists of 36 items
organised in eight domains: physical functioning, role
limitations caused by physical health problems, bodily
pain, general health perceptions, vitality, social function-
ing, role limitations caused by emotional problems and
mental health. The SF-36 is scored from 0 to 100, with
higher scores indicating better health-related QoL. Two
comprehensive indices of health-related QoL can also be
computed: physical component summary, summarizing
the first four domains, and mental component summary,
summarizing the last four domains. SF-36 has previously
been used for the assessment of QoL in patients with
chronic liver disease [17,19-21]. Normative data from the
Swedish general population are available, as well as thor-
ough assessment of validity and reliability of the Swedish
version of SF-36 [27].
Statistics
Data are expressed as mean (SD). The student's t-test or
the Mann-Whitney test was performed as appropriate in
order to compare continuous variables. The Chi-square or
the Fisher's exact test was used as appropriate for compar-
isons between categorical variables. The Pearson's correla-
tion coefficient was calculated for correlation analysis
between continuous variables. For multiple comparisons
among groups one-way ANOVA for continuous variables
or chi-square test for categorical variables was performed.
If p < 0.05 the Bonferroni test (continuous variables) or
the chi-square test (categorical variables) was used for
post-hoc comparisons. First, patients with different types
of liver disease (hepatocellular vs. cholestatic) were com-
pared as regards to the presence of hepatic encephalopa-
thy as well as other clinical parameters. Subsequently,
patients with one of the major three etiologies (alcoholic
cirrhosis vs. cirrhosis due to hepatitis C vs. cholestatic cir-
rhosis) were compared. In an attempt to explore inde-
pendent predictors of NCT-A and NCT-B performance
times as well as the SF-36 physical component summary,
all parameters that were univariately correlated at p < 0.1
with these variables, were entered into stepwise linear
multiple regression analyses. All tests were two-tailed and
conducted at a 5% significance level.
Results
A total of 29 patients had cholestatic cirrhosis (11 with
PBC and 18 with PSC) and 127 had hepatocellular cirrho-
sis (55 alcoholic; 37 viral (32 hepatitis C, 5 hepatitis B);
24 mixed alcoholic and viral; 6 autoimmune hepatitis; 4
NASH; one alpha-1-antithrypsine deficiency). Seventeen
out of 79 patients with alcoholic or mixed alcoholic cir-
rhosis admitted to active alcohol overconsumption. The
rest claimed to have been abstinent during the previous
3–6 months but only 28 these were followed-up by a spe-
cialized addiction center and had documented abstinence
(by means of random urine or breath tests).
Hepatic encephalopathy in hepatocellular vs. cholestatic 
cirrhosis
Diabetes mellitus was less common among patients with
cholestatic cirrhosis compared to those with hepatocellu-
lar cirrhosis but the two groups did not differ significantly
in the prevalence of (minimal or overt) hepatic encepha-
lopathy nor in the prevalence of other complications or in
severity of liver cirrhosis (table 1). Patients with PBC vs.
PSC did not differ significantly in the prevalence of (min-
imal or overt) HE or diabetes mellitus nor in the severity
of liver cirrhosis (data not shown). However, there are sig-BMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
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nificant age and gender differences between patients with
PBC and PSC (data not shown) rendering these compari-
sons hard to interpret. Within the group of patients with
alcoholic or mixed alcoholic and viral cirrhosis, the prev-
alence of HE did not differ between patients actively
drinking and patients with documented abstinence from
alcohol (data not shown).
Patients with compared to those without diabetes melli-
tus took longer time to perform NCT-A and B (table 2).
However, the two groups did not differ significantly in the
prevalence of (minimal or overt) hepatic encephalopathy
nor in the severity or prevalence of complications of liver
cirrhosis with the exception of hepatocellular carcinoma
that was more common among patients with diabetes
(table 2). When patients with hepatocellular and choles-
tatic cirrhosis were analyzed separately, diabetes mellitus
was not related to the prevalence of (minimal or overt) HE
in either group (data not shown).
Hepatic encephalopathy in alcoholic cirrhosis vs. cirrhosis 
due to hepatitis C vs. cholestatic cirrhosis
The group of patients with hepatocellular cirrhosis was
heterogeneous. In order to explore the potential effects of
specific etiologies of liver disease on hepatic encephalop-
athy, patients with mixed etiologies or with etiologies rep-
resented in low numbers in the current cohort (i.e.
hepatitis B, NASH, autoimmune hepatitis, and alpha 1-
antithrypsine deficiency) were excluded from further
analysis. Subsequently, the groups of patients with cirrho-
sis due to alcoholic liver disease, hepatitis C, or cholestatic
liver disease were compared to one another (table 3). Dia-
betes mellitus was less common in the group of choles-
tatic cirrhosis, but the three groups did not differ in
severity of liver disease or the prevalence of (minimal or
overt) hepatic encephalopathy (table 3).
Number connection tests A and B performance times
Clinical parameters univariately related at p < 0.1 with the
time needed to perform NCT-A or NCT-B were entered
into stepwise multivariate regression analyses with NCT-A
and NCT-B performance times as the dependent variables
(table 4). The time needed to perform NCT-A was inde-
pendently related to the Child-Pugh score and diabetes
mellitus whereas the time needed to perform NCT-B was
independently related only to the Child-Pugh score and
age (table 4).
Etiology of cirrhosis and health-related QoL
Patients with compared to those without (minimal or
overt) HE had lower SF-36 physical component summary
(30.1 (12.8) vs. 40.6 (10.8), p < 0.001) and mental com-
Table 1: Demographic and clinical characteristics in patients with hepatocellular and cholestatic liver cirrhosis
Hepatocellular cirrhosis (n = 127) Cholestatic cirrhosis (n = 29) p-value
Age 56 (11) 54 (14) 0.496
Female/Male 33/94 (26%/74%) 9/20 (31%/69%) 0.580
Outpatients/inpatients 104/23 (82%/18%) 25/4 (86%/14%) 0.579
Previous variceal bleeding 37 (29%) 8 (28%) 0.953
Esophageal and/or fundic varices 88 (69%) 24 (83%) 0.139
Ascites 55 (43%) 9 (31%) 0.225
Hepatocellular carcinoma 22 (17%) 1 (3.4%) 0.06
Number connection test A
Mean (SD) (sec) 61 (44) 50 (44) 0.258
Above 3 SDa 17 (13%) 3 (10%) 0.567
Number Connection test B
Mean (SD) (sec) 148 (82) 118 (69) 0.08
Above 3 SDa 26 (20%) 4 (14%) 0.303
Overt hepatic encephalopathy 32 (25%) 4 (14%) 0.216
(West-Haven)b
Grade I 30 (23.5%) 3 (10.5%)
Grade II 2 (1.5%) 1 (3.5%)
Minimal hepatic encephalopathyc 9 (7%) 2 (7%) 0.93
Hepatic encephalopathy 41 (32%) 6 (21%) 0.175
(minimal or overt)
Fasting plasma ammonium ion (μmol/l) 58 (37) 52 (21) 0.292
MELD score 13.7 (6.2) 14.3 (5.4) 0.645
Child-Pugh score 8.6 (2.4) 8.8 (2) 0.752
Diabetes Mellitus 44 (35%) 3 (10%) 0.01
Data are presented as mean (SD) or n (%) as appropriate
a Compared to age-corrected normal values from the general population
b Overt hepatic encephalopathy according to West-Haven criteria: none with grade III or IV
c Defined as absence of overt hepatic encephalopathy and number connection test A > 3SD and/or number connection test B > 3SDBMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
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ponent summary (36.4 (12.8) vs. 41.8 (14.4), p < 0.05).
However, etiology of liver cirrhosis was not related to
health-related QoL (figure 1). All parameters in table 3
that were univariately related to the SF-36 physical com-
ponent summary at p < 0.1 were entered into a stepwise
regression analysis. Only the Child-Pugh score (unstand-
ardized beta coefficient = -1.36, p = 0.01) and HE
(unstandardized beta coefficient = -3.59, p = 0.012) were
independently related to the SF-36 physical component
summary.
Discussion
In the current study, the etiology of liver cirrhosis was not
related to HE or health-related QoL. Diabetes mellitus was
more common among patients with hepatocellular cir-
rhosis compared to those with cholestatic cirrhosis, in
accordance to published data [7], and neither cirrhosis
severity nor the prevalence of HE differed between the two
groups. Furthermore, the prevalence of HE did not differ
among the groups of cirrhosis due to alcohol, chronic
hepatitis C, or cholestatic liver disease. To our knowledge,
this is the first study to investigate the impact of etiology
of cirrhosis on minimal and overt HE, as assessed accord-
ing to currently accepted criteria [16], with simultaneous
assessment of diabetes mellitus and measurement of
plasma ammonia levels.
These findings are in line with previous reports on the
relation of cognitive impairment with the etiology of liver
disease [4,13,14,28]. Despite initial reports that cognitive
impairment detected by means of neuropsychological
testing varied according to the type -hepatocellular vs.
cholestatic- of cirrhosis [3], a subsequent study demon-
strated that cerebral computed tomography scan abnor-
malities were similarly common in both hepatocellular
and cholestatic liver disease [4]. A recent investigation
showed that cognitive dysfunction was frequent in PBC
patients and unrelated to the severity of liver disease [12].
However, few of the patients included in this study had
frank cirrhosis and patients with PBC were not compared
with controls with another chronic liver disease [12].
Therefore, these findings may not be extrapolated to cir-
rhotic populations due to PBC or PSC.
In previous imaging studies cerebral abnormalities have
been detected with computed tomography in non-alco-
holic cirrhotic patients [29] as well as with magnetic reso-
nance imaging in cirrhotic patients irrespective of liver
disease etiology [30]. Although cirrhotic alcoholics have
been reported to exhibit more gross pathology than non-
alcoholic cirrhosis on ratings of cerebral atrophy assessed
by computed tomography in another imaging study, the
authors noted that the two groups were more similar to
Table 2: Demographic and clinical characteristics in patients with and without diabetes mellitus
With Diabetes (n = 47) Without Diabetes (n = 109) p-value
Age 58 (12) 54 (11) 0.055
Female/Male 8/39 (17%/83%) 34/75 (31%/69%) 0.07
Outpatients/inpatients 41/6 (87%/13%) 88/21 (81%/19%) 0.325
Previous variceal bleeding 11 (23%) 34 (32%) 0.309
Esophageal and/or fundic varices 30 (77%) 82 (79%) 0.804
Ascites 19 (40%) 45 (41%) 0.920
Hepatocellular carcinoma 11 (23%) 12 (11%) 0.045
Number connection test A
Mean (SD) (sec) 73 (62) 53 (33) 0.012
Above 3 SDa 9 (19%) 11 (10%) 0.122
Number Connection test B
Mean (SD) (sec) 164 (93) 132 (72) 0.035
Above 3 SDa 10 (21%) 20 (18%) 0.726
Overt hepatic encephalopathy 14 (30%) 22 (20%) 0.202
(West-Haven)b
Grade I 12 (25.5%) 21 (19%)
Grade II 2 (4.5%) 1 (1%)
Minimal hepatic encephalopathyc 3 (6%) 8 (7%) 0.83
Hepatic encephalopathy 17 (36%) 30 (27%) 0.274
(minimal or overt)
Fasting plasma ammonium ion (μmol/l) 60 (37) 55 (34) 0.433
MELD score 13.7 (6.5) 13.9 (5.8) 0.895
Child-Pugh score 8.6 (2.2) 8.7 (2.4) 0.883
Data are presented as mean (SD) or n (%) as appropriate
a Compared to age-corrected normal values from the general population
b Overt hepatic encephalopathy according to West-Haven criteria: none with grade III or IV
c Defined as absence of overt hepatic encephalopathy and number connection test A > 3SD and/or number connection test B > 3SDBMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
Page 6 of 9
(page number not for citation purposes)
each other than they were different on planimetric meas-
urements [31]. Cognitive impairment has been observed
in non-cirrhotic patients with alcoholism [8] and with
chronic hepatitis C [10,11,32]. However, in some hepati-
tis C cohorts cognitive decline has not been shown to dif-
fer from that of patients with chronic liver disease of other
etiologies [10,32]. Liver disease severity is thought to be
the main determinant of cognitive dysfunction in alco-
holic cirrhosis [13,14,28] although some controversy
exists [33]. In a recent study in patients with cirrhosis
without overt HE (according to the West Haven criteria),
minimal HE was proposed to be more common in cir-
rhotic patients with hepatitis C [34]. However, this differ-
ence was only observed in univariate analysis of data and
Table 3: Demographic and clinical characteristics in patients with cirrhosis due to alcoholic liver disease, hepatitis C, and cholestatic 
liver disease
Alcoholic liver cirrhosis (n = 55) Hepatitis C cirrhosis (n = 32) Cholestatic cirrhosis (n = 29)
Age 60 (8) * 54 (7) 54 (14)
Female/Male 12/43 (22%/78%) 9/23 (28%/72%) 9/20 (31%/69%)
Outpatients/inpatients 42/13 (76%/24%) 27/5 (84%/16%) 25/4 (86%/14%)
Previous variceal bleeding 15 (27%) 7 (22%) 8 (28%)
Esophageal and/or fundic varices 37 (67%) 21 (66%) 24 (83%)
Ascites 31 (56%)* 10 (31%) 9 (31%)
Hepatocellular carcinoma 6 (11%) 9 (28%)* 1 (3.4%)
Number connection test A
Mean (SD) (sec) 68 (51) 52 (33) 50 (44)
Above 3 SDa 10 (18%) 2 (6%) 3 (10%)
Number Connection test B
Mean (SD) (sec) 165 (87) 141 (83) 118 (69)
Above 3 SDa 13 (24%) 5 (16%) 4 (14%)
Overt hepatic encephalopathy 15 (27%) 6 (19%) 4 (14%)
(West-Haven)b
Grade I 14 (25.5%) 6 (19%) 3 (10.5%)
Grade II 1 (2%) 0 1 (3.5%)
Minimal hepatic 4 (7%) 2 (6%) 2 (7%)
encephalopathyc 19 (34%) 8 (25%) 6 (21%)
Hepatic encephalopathy
(minimal or overt)
Fasting plasma ammonium ion (μmol/l) 50 (26) 51 (35) 52 (21)
MELD score 14.9 (7.2) 12.6 (5) 14.3 (5.4)
Child-Pugh score 9 (2.6) 8.2 (2.2) 8.8 (2)
Diabetes mellitus 20 (36%) 11 (34%) 3 (10%)*
Data are presented as mean (SD) or n (%) as appropriate
a Compared to age-corrected normal values from the general population
b Overt hepatic encephalopathy according to West-Haven criteria: none with grade III or IV
c Defined as absence of overt hepatic encephalopathy and number connection test A > 3SD and/or number connection test B > 3SD
For comparisons of continuous variables if one-Way ANOVA was significant (p < 0.05), the post-hoc Bonferroni test was used for comparisons 
among different groups.
For comparisons of if the chi-square test was significant (p < 0.05) when data from all groups were tested, the chi-square test was used for post-hoc 
analysis among different groups
*p < 0.05 compared to the other two groups
Table 4: Factors independently correlated to the time needed to perform number connection test A and B after multivariate analysis 
in patients with liver cirrhosis (n = 156)
Adjusted R2 % (for whole model) Unstandardized beta coefficient
Time needed to perform NCT-A 20.3
Child-Pugh score 6.37**
Diabetes mellitus 16.9*
Time needed to perform NCT-B 29.9
Child-Pugh score 12.4**
Age (per year) 2.84**
* p < 0.05, **p < 0.001BMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
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was not tested in multivariate analysis [34]. Apart from
this report data comparing cognitive function of patients
with hepatitis C cirrhosis with that of patients with cirrho-
sis due to other etiologies are largely lacking. Our findings
support previously published data that alcoholic etiology
is not a major determinant of cognitive dysfunction in cir-
rhotic patients [13,14,28] and further indicate that neither
hepatitis C nor cholestatic liver disease have a major effect
on hepatic encephalopathy in cirrhosis.
Diabetes mellitus has been shown to be associated to HE
in hepatitis C cirrhosis [5]. Insulin resistance, which is
common in cirrhotic patients, is also related to plasma
ammonia levels [6]. We did observe an independent rela-
tion of diabetes mellitus with the time needed to perform
NCT-A, in accordance with a previous report [6], but dia-
betes did not affect the prevalence of HE in our patient
cohort. The same was true when the potential effect of dia-
betes on HE was analyzed separately in the subgroups of
hepatocellular or cholestatic cirrhosis. Although our study
was not designed to assess the impact of diabetes on HE
our results indicate that factors other than diabetes melli-
tus might be more important in determining HE in cirrho-
sis of various etiologies.
Most previous studies have not detected any difference in
health-related QoL indices among patients with liver cir-
rhosis of different etiologies [17,19,20]. Younossi et al
compared health-related QoL in patients with hepatocel-
lular and cholestatic cirrhosis and found that physical
dimensions of QoL were less impaired in patients with
cholestatic disease than in those with hepatocellular dis-
ease [18]. We found that health-related QoL was related to
hepatic encephalopathy in line with previously published
data [17,21] but we did not observe any significant differ-
ences in any QoL dimension between hepatocellular and
cholestatic cirrhosis. These apparently different findings
may be explained by the different patient groups recruited
in the two studies. In the study of Younossi et al the group
of hepatocellular cirrhosis consisted mainly of patients
with alcoholic and cryptogenic cirrhosis as well as patients
with autoimmune hepatitis [18]. On the other hand,
patients with cryptogenic cirrhosis were excluded from the
current investigation and 39/127 patients with hepatocel-
lular disease had viral cirrhosis. Furthermore, in the previ-
ous study the proportion of patients with Child-Pugh C
cirrhosis was 3.3% in the cholestatic and 26.6% in the
hepatocellular group [18] whereas there were not any sig-
nificant differences in cirrhosis severity between the two
Health-related quality of life assessed as mean SF-36 domain and summary scores in patients with liver cirrhosis with different  etiologies (totally n = 156) Figure 1
Health-related quality of life assessed as mean SF-36 domain and summary scores in patients with liver cirrho-
sis with different etiologies (totally n = 156). Mean SF-36 domain and summary scores did not differ significantly among 
different groups (p > 0.05 for all). PF, physical functioning; RP, role limitations caused by physical health problems; BP, bodily 
pain; GH, general health perceptions; VT, vitality; SF, social functioning; RE, role limitations caused by emotional problems; MH, 
mental health; PCS, physical component summary; MCS, mental component summary.BMC Gastroenterology 2008, 8:46 http://www.biomedcentral.com/1471-230X/8/46
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groups in the current study. Our findings are in accord-
ance with previously published data indicating HE and
cirrhosis severity are important determinants of QoL in
cirrhosis whereas the etiology of liver disease does not
seem to play a major role [17,20,21].
Certain methodological limitations of the currents study
should be taken into consideration. First, HE was evalu-
ated by means of clinical assessment and psychometric
tests but no quantitative neurophysiologic tools (such as
electroencephalography) were used. Although neurophys-
iologic tools are often used in research studies there is no
clear consensus as to the validity of these tests when used
alone or in combination [35]. In the current study, the
guidelines of the 11th World Congress of Gastroenterology
were followed in the evaluation of HE [16]; clinical assess-
ment and simple bedside psychometric tests were chosen
as they are easily applied in everyday practice. Second,
although in the current study no major differences were
observed in demographic variables or in severity of liver
disease among groups of patients with different etiologies,
ideally patients in the different groups should be matched
for age, gender, and severity of liver disease. Third, the cur-
rent study is a cross-sectional one. Thus, a cause-effect
relationship between the measured variables would be
hard to establish. Last, although our investigation is the
largest, to date, exploring the relation of the type of liver
cirrhosis (cholestatic vs. hepatocellular) with the presence
of hepatic encephalopathy and although all patients with
cholestatic cirrhosis under our care were asked to partici-
pate, a type-II error cannot be excluded. Further multi-
center studies might be necessary to fully delineate the
potential role of the type and etiology of cirrhosis in
hepatic encephalopathy.
Conclusion
We conclude that the etiology of liver disease is not
related to hepatic encephalopathy or health-related QoL
in liver cirrhosis. Performance at psychometric testing is
affected by age, diabetes mellitus, and cirrhosis severity.
Although diabetes mellitus was more common among
patients with hepatocellular compared to those with
cholestatic cirrhosis, the prevalence of HE did not differ
between the two groups.
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